$MNKD Sadly $LQDA is not the first company that we have seen leave $MNKD in the dust. Companies like $DXCM and $ARNA used to trade for less than MNKD and we have sat back and watched them grow to 10, 50, 100x MNKD's value, all while watching MNKD decay, while the CEO has his lackies make charts of other insulin product growth (which all outpaced MNKD) and says it takes time to shift a paradigm.
@Riteman I bought $ARNA expecting a buyout and it happened. I bought $VRNA expecting a buyout and it happened. I starting buying $SLS 2 months ago and I expect a buyout.
$KPTI filing today: T. Row Price more than doubled their position from 700k to 1.5M shares. They were also a top holder of $ARNA and stayed with the company which was sold to $PFE Pfizer. But ARNA brought a CEO who had turnaround experience and the stock took off. Richard Paulson is a horrible CEO who's decimated KPTI. But I'm hanging in there.
$SMX I got off work from Amazon one morning, I put up $27K and was up 9k and those 2 cheap beers made me fall asleep and I woke up down $11K, but in 2012 in $ARNA I was up $30K in 5 days got greedy bought $127K worth in premarket and the shorts colluded and sold a institutional block at 9:20am at $5 when the stock was at $12 - no stop loss but still loss 18k in 30mins
$SLS LET’S GOOOO. It reminds me of $ARNA (Arena Pharm), which was held back for years by shorts but ultimately rose up to $90+ with a buyout deal. This could be even better/bigger. 🙏🙏🙏 GLTAL!
$SLS price chart goes straight down? Market manipulation!!! Shorts playing games because they’re trapped. Saw this happen with $ARNA. They held it down but it eventually went up to $90+. Know what you own. Hold and buy on the dips!
$SLS reminds me of what happened to $ARNA. Shorts tried to hold it down as long as possible, but it eventually hit $90+. I sold at $70. Bought at $13. Have faith. If price dips, load the boat. You know what you own.
$PPBT
Why It Matters
• Market cap still under $4M
• Volume surging—not retail behavior
• Leadership with billion-dollar biotech wins
• NT‑219 targets tumor resistance + immune evasion
• Setup mirrors past breakout plays like $IMMU and $ARNA
$PPBT
The Biotech Playbook in Motion
Volume spikes. Price suppression. Troll surge.
Seen it before: $IMMU, $ARNA, $TRIL.
Same setup. Same silence. Same endgame.
Retail’s not rattled. Shorts are.
$PPBT
Biotech playbook 101.
Volume ramps, Price gets walked down. Trolls flood the boards. Shorts go silent. Retail starts second-guessing.
Seen it with $IMMU before Gilead’s $21B buyout. $ARNA before Pfizer’s $6.7B deal. Same setup: fear, silence, accumulation.
KRAS-agnostic synergy. ESMO data incoming. Bio Europe spotlight.
Market cap still under $4M.
This isn’t noise—it’s the setup. 🧬
@Jsgribbs I have owned $ARNA for years now and this short squeeze story has been constant. A short squeeze is unlikely because shorts are fully hedged - there are virtually no retail shorts here.
@SniperPro I mean wasn't $ARNA at like $50/share before the announcement? Also, what drugs did they offer that prompted this merger? I am not saying you're wrong, but I do say there can be a lot more information added to this.
